

Policy Title:	Onpattro (patisiran lipid complex) (Intravenous)		
		Department:	PHA
Effective Date:	04/10/2019		
Review Date:	11/27/2019, 1/29/20, 6/10/2021, 12/15/2022, 5/4/2023, 12/07/2023, 01/04/2024		

Purpose: To support safe, effective, and appropriate use of Onpattro (patisiran lipid complex).

Scope: Medicaid, Commercial, Medicare-Medicaid Plan (MMP)

Policy Statement:

Onpattro (patisiran lipid complex) is covered under the Medical Benefit when used within the following guidelines. Use outside of these guidelines may result in non-payment unless approved under an exception process.

Procedure:

Coverage of Onpattro (patisiran lipid complex) will be reviewed prospectively via the prior authorization process based on criteria below.

Initial Criteria:

Polyneuropathy due to Hereditary Transthyretin-Mediated (hATTR) Amyloidosis/Familial Amyloidotic Polyneuropathy (FAP)

- Patient must be at least 18 years old; AND
- Patient is receiving supplementation with vitamin A at the recommended daily allowance; AND
- Must be prescribed by or in consultation with a neurologist, or physician specializing in the treatment of amyloidosis related to hATTR/FAP; AND
- Patient has a definitive diagnosis of hATTR amyloidosis/FAP as documented by amyloid deposition on tissue biopsy and identification of a pathogenic *TTR* variant using molecular genetic testing; AND
- Used for the treatment of polyneuropathy as demonstrated by at least TWO of the following criteria:
 - Subjective patient symptoms are suggestive of neuropathy
 - Abnormal nerve conduction studies are consistent with polyneuropathy
 - Abnormal neurological examination is suggestive of neuropathy; AND
- Patient's peripheral neuropathy is attributed to hATTR/FAP and other causes of neuropathy have been excluded; AND
- Baseline in strength/weakness has been documented using an objective clinical measuring tool (e.g., Medical Research Council (MRC) muscle strength, etc.); AND
- Patient has not been the recipient of an orthotopic liver transplant (OLT); AND

- The requested medication will not be used in combination with other transthyretin (TRR) reducing agents [e.g. inotersen (Tegsedi), tafamidis (Vyndaqel/Vyndamax), Amvuttra(vutrisiran) etc.]; AND
- Onpattro (patisiran) is unproven and not medically necessary for the treatment of:
 - Sensorimotor or autonomic neuropathy not related to hATTR amyloidosis
 - Primary or leptomeningeal amyloidosis
 - Cardiomyopathy hATTR
- MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements

Continuation of Therapy Criteria:

- Meet all initial approval criteria AND is tolerating treatment; AND
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include the following: severe infusion-related reactions, ocular symptoms related to hypovitaminosis A, etc.; AND
- Disease response compared to pre-treatment baseline as evidenced by stabilization or improvement in one or more of the following:
 - Signs and symptoms of neuropathy
 - MRC muscle strength

Coverage durations:

- Initial coverage: 6 months
- Continuation of therapy coverage: 6 months

Per §§ 42 CFR 422.101, this clinical medical policy only applies to INTEGRITY in the absence of National Coverage Determination (NCD) or Local Coverage Determination (LCD).

Dosage/Administration:

Indication	Dose	Maximum dose (1 billable unit = 0.1 mg)
hATTR/ FAP	<ul style="list-style-type: none"> • Weight < 100 kg: 0.3 mg/kg intravenously every 3 weeks • Weight ≥ 100 kg: 30 mg intravenously every 3 weeks 	300 billable units (30 mg) every 3 weeks

Investigational use: All therapies are considered investigational when used at a dose or for a condition other than those that are recognized as medically accepted indications as defined in any one of the following standard reference compendia: American Hospital Formulary Service Drug information (AHFS-DI), Thomson Micromedex DrugDex, Clinical Pharmacology, Wolters Kluwer Lexi-Drugs, or Peer-reviewed published medical literature indicating that sufficient evidence exists

to support use. Neighborhood does not provide coverage for drugs when used for investigational purposes.

Applicable Codes:

Below is a list of billing codes applicable for covered treatment options. The below tables are provided for reference purposes and may not be all-inclusive. Requests received with codes from tables below do not guarantee coverage. Requests must meet all criteria provided in the procedure section.

The following HCPCS/CPT codes are:

HCPCS/CPT Code	Description
J0222	Injection, patisiran, 0.1mg

References:

1. Onpattro [package insert]. Cambridge, MA; Alnylam Pharmaceuticals, Inc., January 2023. Accessed November 2023.
2. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. *N Engl J Med.* 2018 Jul 5;379(1):11-21. doi: 10.1056/NEJMoa1716153
3. Adams D, Suhr OB, Dyck PJ, et al. Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy. *BMC Neurol.* 2017;17(1):181
4. Sekijima Y, Yoshida K, Tokuda T, et al. Familial Transthyretin Amyloidosis. *Gene Reviews.* Adam MP, Ardinger HH, Pagon RA, et al., editors. Seattle (WA): University of Washington, Seattle; 1993-2018.